U.S. Stock Market Midday Update: Jyong Biotech plummets 24.61%, with a year-to-date increase of 54.80% attracting market volatility attention

U.S. Stock Market Midday Update Jyong Biotech, down 24.61%, has a year-to-date increase of 54.80%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Gilead Sciences down 0.05%. Based on recent news, On December 15, Gilead Sciences' Chief Commercial Officer Johanna Mercier and Chief Financial Officer Andrew D. Dickinson each sold shares of the company's common stock. Mercier sold 3,000 shares worth $366,000, and Dickinson also sold 3,000 shares worth $366,000. These transactions may have raised market concerns about insider confidence in the company, leading to a decline in stock price. On December 15, Gilead Sciences announced that its experimental HIV treatment met its primary endpoint in a late-stage trial. Although this news has a positive impact on the company's long-term strategy, it failed to significantly boost the stock price in the short term. On December 16, Gilead Sciences' stock rose 2% in pre-market trading but then fell back, indicating a complex market reaction to the company's recent news. The competition in the HIV treatment field is fierce, and there is uncertainty regarding market acceptance of new therapies. Precision Sciences up 0.02%. Precision Sciences up 0.02%. No significant news recently; trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Recursion up 11.55%. Based on recent key news: On December 17, JP Morgan upgraded Recursion Pharmaceuticals from Neutral to Overweight and raised the target price to $11 per share. This rating adjustment provided significant upward momentum for the stock price, leading to a 7.4% increase. On December 17, market attention on Recursion Pharmaceuticals increased, with significantly enlarged trading volume, indicating heightened investor interest in the stock. On December 17, although Recursion Pharmaceuticals was not listed among the top five stocks recommended by market analysts, its rating adjustment still attracted investor attention. The tech biotech sector has been active recently, with noticeable capital inflow. Stocks with High Market Capitalization in the Industry AbbVie up 0.18%. Based on recent news, On December 17, market analysis indicated that although AbbVie is currently rated as "Moderate Buy," top analysts believe there are five stocks with greater investment value. This news may lead some investors to reassess their holdings, impacting the stock price On December 16th, market analysis pointed out that AbbVie failed to make the list of the top five stocks recommended by analysts, which may have raised concerns among investors and led to stock price fluctuations. On December 15th, a market analysis report showed that although AbbVie was rated as "Moderate Buy," it failed to make the list of the top five stocks recommended by analysts, which may negatively impact investor confidence. Market analysts rated AbbVie as "Moderate Buy."